ImpriMed, a Palo Alto, CA-based creator and researcher of custom, precision cancer treatment for canines, raised $4m in funding.
This financing includes $3.7m in seed funding led by Draper Associates, and a previously unannounced $330k thousand pre-seed round led by Plug & Play Ventures. Other backers included Murex Partners, and the Stanford-StartX Fund.
The company intends to use the funds to roll out a clinical trial, which will be performed primarily at SAGE Veterinary Centers in the Bay Area.
Founded in 2017 by Hye Ryeon Lee, COO, and Sungwon Lim, CEO, ImpriMed uses precision medicine techniques to allow veterinary oncologists to find out appropriate chemotherapies for individual dogs with cancer. Measuring hundreds of different drug responses on the patient’s fresh biopsy samples, the company’s platform observes how the live cancer cells react, before actual drug treatment. It screens the most effective treatment options and excludes out non-effective ones as evidenced by testing, and provides this information to veterinarians to be administered to each specific patient as appropriate. Currently, lymphoma is the specific form of cancer that ImpriMed is focusing on treating in dogs.
The company aims to help treat more than 500 dogs by 2020, and is offering their service for free of charge for a limited time before completing their clinical trial.
ImpriMed has an additional presence in Seoul, South Korea.